IDEXX Laboratories (IDXX) vs Natera (NTRA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Natera (NTRA) has outperformed IDEXX Laboratories (IDXX) over the past year, gaining 127.1% versus a loss of 18.5%. Over five years, NTRA leads with a +252.8% price change compared with -19.2% for IDXX. Natera is the larger company by market cap ($57.14 billion vs $40.76 billion), about 1.4 times the size.
IDEXX Laboratories converts more of its revenue into profit, with a net margin of 24.6% versus -9.0%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | IDXX | NTRA |
|---|---|---|
| Share price | $517.35 | $396.44 |
| Market cap | $40.76B | $57.14B |
| 1-day change | +0.82% | +1.45% |
| YTD return | -24.15% | +70.58% |
| 1-year return | -18.54% | +127.08% |
| 5-year return | -19.21% | +252.79% |
| P/E ratio (TTM) | 36.36 | — |
| Forward P/E | 30.91 | — |
| EPS (TTM) | $14.23 | $-1.35 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $4.30B | $2.31B |
| Revenue growth (YoY) | +10.42% | +35.90% |
| Net income (latest FY) | $1.06B | $-208.16M |
| Gross margin | 61.80% | — |
| Operating margin | 31.60% | -13.44% |
| Net margin | 24.62% | -9.03% |
| 52-week high | $769.98 | $437.41 |
| 52-week low | $500.61 | $167.99 |
| Distance from 52-week high | -32.81% | -9.37% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +35.56% | -4.80% |
| Average volume | 553.95K | 1.45M |
| Shares outstanding | 78.78M | 144.14M |
| Employees | 11,000 | 6,135 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: In Vitro & In Vivo Diagnostic Substances | Medical Specialities |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- NTRA has outperformed IDXX by 145.6 percentage points over the past year.
- IDEXX Laboratories is more profitable, keeping 24.6 cents of every revenue dollar as net income versus -9.0 cents for Natera.
- Natera grew revenue faster in its latest fiscal year (+35.90% vs +10.42%).
About IDEXX Laboratories
IDXX stock →IDEXX Laboratories, Inc. develops, manufactures, and distributes products for the companion animal veterinary, livestock and poultry, dairy, and water testing industries in the United States and internationally.
Health Care · Biotechnology: In Vitro & In Vivo Diagnostic Substances · 11,000 employees
About Natera
NTRA stock →Natera, Inc., a diagnostics company, engages in the development and commercialization of molecular testing services worldwide. It offers Signatera, a personalized ctDNA blood test for MRD assessment, early recurrence monitoring, and evaluation of treatment response in patients previously diagnosed with cancer; Latitude, a blood-based MRD test for colorectal cancer; Altera, a tissue based comprehensive genomic profiling test; and Empower, a hereditary cancer screening test.
Health Care · Medical Specialities · 6,135 employees
IDXX vs NTRA FAQ
Which is bigger, IDEXX Laboratories or Natera?
Natera (NTRA) is larger, with a market capitalization of $57.14B compared with $40.76B for IDEXX Laboratories (IDXX).
Which stock has performed better over the past year, IDXX or NTRA?
NTRA returned +127.08% over the past 12 months, compared with -18.54% for IDXX (price return, excluding dividends). Past performance does not predict future results.
Are IDEXX Laboratories and Natera in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: In Vitro & In Vivo Diagnostic Substances for IDEXX Laboratories and Medical Specialities for Natera.